MyoKardia, Inc. (NASDAQ:MYOK) will hold its 2Q20 earnings conference call with the financial community on 4th August 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at www.myokardia.com
Earnings Expectation
MyoKardia, Inc. is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 1.46 per share. Looking ahead, the full year loss are expected at $ 6.04 per share.
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart.
